In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Cardlytics Inc (NASDAQ: CDLX) closed the day trading at $1.03 down -5.50% from the previous closing price of $1.09. In other words, the price has decreased by -$5.50 from its previous closing price. On the day, 1.34 million shares were traded. CDLX stock price reached its highest trading level at $1.09 during the session, while it also had its lowest trading level at $1.03.
Ratios:
For a better understanding of CDLX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.16. In the meantime, Its Debt-to-Equity ratio is 3.75 whereas as Long-Term Debt/Eq ratio is at 2.95.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Evercore ISI on October 11, 2024, initiated with a In-line rating and assigned the stock a target price of $4.
On August 16, 2024, Northland Capital Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $5.
BofA Securities Downgraded its Neutral to Underperform on August 15, 2024, whereas the target price for the stock was revised from $4 to $3.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 18 ’25 when SOSIN CLIFFORD sold 200,000 shares for $1.14 per share. The transaction valued at 228,220 led to the insider holds 5,399,023 shares of the business.
SOSIN CLIFFORD sold 200,000 shares of CDLX for $224,540 on Aug 19 ’25. The 10% Owner now owns 5,199,023 shares after completing the transaction at $1.12 per share. On Aug 18 ’25, another insider, Gupta Amit, who serves as the Chief Executive Officer of the company, sold 68,260 shares for $1.12 each. As a result, the insider received 76,792 and left with 560,444 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDLX now has a Market Capitalization of 54834004 and an Enterprise Value of 231695216. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.21 while its Price-to-Book (P/B) ratio in mrq is 0.93. Its current Enterprise Value per Revenue stands at 0.87 whereas that against EBITDA is -7.354.
Stock Price History:
The Beta on a monthly basis for CDLX is 1.22, which has changed by -0.73657286 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, CDLX has reached a high of $5.24, while it has fallen to a 52-week low of $0.95. The 50-Day Moving Average of the stock is -39.69%, while the 200-Day Moving Average is calculated to be -58.31%.
Shares Statistics:
Over the past 3-months, CDLX traded about 1.43M shares per day on average, while over the past 10 days, CDLX traded about 1351050 shares per day. A total of 52.99M shares are outstanding, with a floating share count of 50.33M. Insiders hold about 5.46% of the company’s shares, while institutions hold 45.44% stake in the company. Shares short for CDLX as of 1753920000 were 6438256 with a Short Ratio of 4.50, compared to 1751241600 on 7443027. Therefore, it implies a Short% of Shares Outstanding of 6438256 and a Short% of Float of 14.099999999999998.
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of Cardlytics Inc (CDLX) in the stock market.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.04 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.46 and -$0.8 for the fiscal current year, implying an average EPS of -$0.62. EPS for the following year is -$0.45, with 3.0 analysts recommending between -$0.3 and -$0.61.
Revenue Estimates
4 analysts predict $56.64M in revenue for the current quarter. It ranges from a high estimate of $63.8M to a low estimate of $53.07M. As of the current estimate, Cardlytics Inc’s year-ago sales were $67.06MFor the next quarter, 4 analysts are estimating revenue of $58.85M. There is a high estimate of $62.8M for the next quarter, whereas the lowest estimate is $55.81M.
A total of 4 analysts have provided revenue estimates for CDLX’s current fiscal year. The highest revenue estimate was $243.4M, while the lowest revenue estimate was $234.03M, resulting in an average revenue estimate of $238.54M. In the same quarter a year ago, actual revenue was $278.3MBased on 5 analysts’ estimates, the company’s revenue will be $228.85M in the next fiscal year. The high estimate is $250.1M and the low estimate is $202.24M.
